CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 861 enrolled
Drug / intervention
Bepreve +1 moredrug
Likely dose
One drop in both eyes, twice dailyAI-extracted
Key inclusion· 2
  • ✓At least 3 years of age
  • ✓Ocular health within normal limits
Key exclusion· 1
  • ✕No active ocular disease

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00586625
NCT00586625Phase 3Completed
CompareCT.gov

Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers

Bausch & Lomb Incorporated·interventional·Posted Jan 4, 2008·Updated Feb 15, 2013

In Brief

A Phase 3 clinical trial evaluating Bepreve and Placebo for Allergic Conjunctivitis. Completed, enrolled 861 participants.

Detailed Summary

Safety study for bepotastine besilate ophthalmic solution in normal volunteers

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 4, 2008
Enrollment StartOct 1, 2007
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 18.5 years ago

Interventions

Beprevedrug

One drop, both eyes, twice a day

Placebodrug

One drop, both eyes, twice a day